renin or prorenin receptor/Wnt pathway dual inhibitors (CCRP Therapeutics)

N/A

Report date: 2025/01/26 16:51:38
NME

Base Information

Drug Namerenin or prorenin receptor/Wnt pathway dual inhibitors (CCRP Therapeutics)
Drug Alias Namerenin or prorenin receptor/Wnt pathway dual inhibitors (CCRP Therapeutics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRenin inhibitorsWingless type MMTV integration site family protein inhibitors
TargetsReninWingless type MMTV integration site family protein
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryDenmark
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCCRP Therapeutics GmbH
China Registration ClassN/A

Develop Information

Active CompaniesCCRP Therapeutics GmbH
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A